Beijing Genomics Institute (BGI) and Diagenode, Inc. Collaborate to Implement Standard Methods in Epigenetics and Next Generation Sequencing Sample Preparation
Published: Aug 23, 2011
BEIJING and BRUSSELS, BELGIUM--(Marketwire - August 23, 2011) -
"Consistency is extremely important, not only for saving reagents and precious samples, but also for creating universal high standards in the emerging field of epigenetics," said Didier Allaer, CEO of Diagenode. "We are very proud to be partnering with BGI in these domains."
"We have been successfully using Diagenode's Bioruptors® and reagents for epigenetics, and in exon sequencing, for years now and have implemented them in all of our facilities across China. We are delighted to be able to expand our collaboration with Diagenode, whose reliability and creativity for improving consistency is proven," said Jihua Sun, Lead of Epigenetics Sequencing Platform, and Renhua Wu, Lead of Exon Sequencing Platform of BGI-Shenzhen.
Diagenode is a multi-national life science company that develops and commercializes innovative instruments and reagents for epigenetic research. Major product lines include: IP-Star® automation system, Bioruptor® sonicator, epigenetic targeted antibodies and kits. Its research and development division is continually improving its technical knowledge of epigenetics marks as evident in Diagenode's Chromatin landscape and DNA methylation analysis offerings which include chromatin immunoprecipitation kits, ChIP-seq internally validated range of antibodies, methylated DNA immunoprecipitation (MeDIP and hMeDIP), bisulfite, methyl binding domain (MBD) protein (also known as MethylCap®) and the gold standard 5-methylcytosine antibody (clone 33D3). Founded in 2004 in Liege (Belgium), Diagenode has offices in Liege, Belgium and Denville, New Jersey.
Head of Global Sales & Marketing
E-mail: Email Contact
North and South American Contact:
US Sales & Marketing Manager